Rutland Herald

Convergent Therapeutics to Present Phase 2 Data for CONV01-α in Lu-PSMA pretreated Metastatic Castration-Resistant Prostate Cancer Patients at the 2026 ASCO Annual Meeting

Convergent Therapeutics Inc., a clinical-stage biotechnology company developing next-generation alpha-emitting radioantibodies for the treatment of advanced prostate cancer, today announced that ...
Business Wire

Convergent Energy and Power Closes Ground-Breaking Financing Facility from Mitsubishi UFJ Financial Group for its Distributed Energy Storage Project Pipeline

NEW YORK--(BUSINESS WIRE)--Convergent Energy and Power (Convergent), a leading provider of distributed energy storage solutions in North America, today announced that it has closed a programmatic ...
Yahoo Finance

Convergent Therapeutics Announces Two Clinical Trial Updates on CONV01-α at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2025

- Phase I Follow-Up Data Showed an Overall Survival of 29.8 Months with the Addition of CONV01-α to 177 Lu-PSMA-I&T in Advanced Prostate Cancer Data showed that the median overall survival was 29.8 ...
Business Wire

Convergent Energy and Power Releases 2022 Sustainability and Impact Report

NEW YORK--(BUSINESS WIRE)--Convergent Energy and Power (Convergent), a leading provider of energy storage solutions in North America, today announced the publication of its 2022 Sustainability and ...